Search

Denis Dupoiron,1 Sabrina Jubier-Hamon,1 Valerie Seegers,2 Florent Bienfait,1 Yves Marie Pluchon,3 Nathalie Lebrec,1 Virginie Jaoul,1 Thierry Delorme1 1Département Anesthésie – Douleur, Institut de Cancérologie de l’Ouest, Angers, France; 2Département de biométrie, Institut de Cancérologie de l’Ouest, Angers, France; 3Centre d’étude et de traitement de la douleur (CETD), Centre hospitalier départemental Vendée, La Roche-sur-Yon, FranceCorrespondence: Denis DupoironDépartement Anesthésie – Douleur, Institut de Cancérologie de l’Ouest, Angers, France, Tel +33 2 41 35 28 73, Email denis.dupoiron@ico.unicancer.frPurpose: Data supporting the use of high-concentration capsaicin patches (HCCPs) in breast cancer (BC) patients and BC survivors (BCSs) with peripheral neuropathic pain (PNP) are limited. This observational study evaluated the effectiveness and safety of HCCP applications in BCSs/BC patients with PNP.Patients and Methods: Data from all patients treated with HCCP in the pain department of a French comprehensive cancer centre were collected from 01-Jan-2014 to 14-Oct-2020. Independent pain specialists completed the Clinical Global Impression of Change (CGIC) for each included patient based on data extracted from patient’s electronic medical record compiled by the treating pain specialist after each HCCP application.Results: Patients (N=279; mean age: 59.2 years; previous history of PNP medication: 54.5%) received on average 4.1 repeated HCCP applications (1141 HCCP applications); 68.8% received HCCP as an add-on to systemic therapy and 27.9% as first-line therapy. PNP was most frequently caused by surgery (62.4%) followed by chemotherapy (11.8%) and radiotherapy (6.5%). A complete or important analgesic effect was reported at least once by 82.3% of patients. A 6.0% reported no effect at all. For post-surgical PNP existing for < 12 months and > 10 years an important or complete effect was observed for 70.7% and 56.0% of applications. For chemotherapy- or radiotherapy-induced PNP, this important or complete effect was observed for 52.7% and 52.3% of applications, respectively. HCCP application was associated with site reactions in 54.4% of patients (mainly burning sensation or pain, 45.9%, or erythema, 30.8%) and high blood pressure in 7.2%.Conclusion: This real-world chart review provides important effectiveness and safety information to clinicians when considering topical options to treat PNP in BCSs/BC patients.Keywords: breast cancer, capsaicin, chronic pain, effectiveness, peripheral neuropathic pain, safety, topical administration